NG-350a is under clinical development by Akamis Bio and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NG-350a’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NG-350a overview
NG-350a is under development for the treatment of relapsed or refractory advanced metastatic epithelial tumors, rectal cancer, ureter, bladder, urethra, head and neck cancer squamous cell carcinoma, squamous non-small cell lung cancer, non-small cell lung cancer, uterine cancer, endometrial cancer, cervical cancer, esophageal cancer, hepatocellular carcinoma, triple-negative breast cancer (TNBC), gastric or gastroesophageal junction adenocarcinoma and metastatic adenocarcinoma of pancreas. It is administered through intravenous and intratumoral routes. The therapeutic candidate is a tumor-selective and blood stable oncolytic adenoviral T-SIGn vector expressing a fully human IgG agonistic anti-CD40 antibody (mAb). It is developed based on the T-SIGn tumor specific delivery platform and AbEnAd technology.
Akamis Bio overview
Akamis Bio, formerly PsiOxus Therapeutics Ltd, develops and discovers novel therapies for the treatment of cancer and other related diseases. The company utilizes T-SIGn, a tumor-specific immune gene platform to develop gene therapies for primary and metastatic solid tumors. Its platform has capabilities to be used in combination with CAR-T and other cell therapies to overcome poor immune cell infiltration, immunosuppressive properties of tumor microenvironment, and systematic toxicity issues. Akamis Bio’s product pipeline includes NG-350A and NG-641 to treat metastatic and advanced epithelial tumors. The company is also investigating NG-347, NG-348, and NG-796A drug programs for application in various cancer treatments. It operates in the US and the UK. Akamis Bio is headquartered in Abingdon, Oxfordshire, the UK.
For a complete picture of NG-350a’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
